English
Home > Products > CAS NO 139504-50-0

China CAS NO 139504-50-0 Factory

The corporation upholds the philosophy of ""Be No.1 in excellent, be rooted on credit rating and trustworthiness for growth"", will proceed to provide aged and new buyers from home and abroad whole-heatedly for CAS NO 139504-50-0,139504-50-0,Mertansine, Warmly welcome to cooperate and develop with us! we will continue to provide product with high quality and competitive price.
CAS NO 139504-50-0, Besides strong technical strength, we also introduce advanced equipment for inspection and conduct strict management. All the staff of our company welcome friends both at home and abroad to come for visits and business on the basis of equality and mutual benefit. If you are interested in any of our objects, remember to feel free to contact us for quotation and product details.

Related Products

Hot Products

  • Dextran

    Dextran

    Product Name:Dextran
    Molecular Formula:C17H32O10
    Molecular Weight;396.42998
    CAS Registry Number;9004-54-0
  • Oseltamivir HCl

    Oseltamivir HCl

    Product Name:Oseltamivir HCl
    Molecular Formula:C16H29ClN2O4
    Molecular Weight;348.87
    CAS Registry Number;204255-09-4
  • 4-Morpholineacetic acid

    4-Morpholineacetic acid

    Product Name:4-Morpholineacetic acid
    Molecular Formula:C6H11NO3
    Molecular Weight:145.16
    CAS Registry Number:3235-69-6
  • CLEBOPRIDE MALATE

    CLEBOPRIDE MALATE

    Product Name:CLEBOPRIDE MALATE
    Molecular Formula:C23H28ClN3O6
    Molecular Weight;477.94
    CAS Registry Number;57645-91-7
  • Diisopropyl azodicarboxylate

    Diisopropyl azodicarboxylate

    Product Name:Diisopropyl azodicarboxylate
    Molecular Formula:C8H14N2O4
    Molecular Weight:202.21
    CAS Registry Number:2446-83-5
  • Irinotecan

    Irinotecan

    Product Name:Irinotecan
    Molecular Formula:C33H38N4O6
    Molecular Weight;586.68
    CAS Registry Number;97682-44-5
  • Related Blog
  • Reviews

  • What are pharmaceutical intermediates?

    Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • What is an Active Pharmaceutical Ingredient (API in Pharma)?

    Sandoo Pharmaceutical is a professional active pharmaceutical intermediate manufacturer, producing high quality APIs. Sandoo Pharmaceutical provides a wide range of active pharmaceutical intermediates.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept